Endeavour Medtech Amends RMBS Stake; Signals Portfolio Adjustment

TL;DR

**Big investor Endeavour Medtech just updated their stake in Rapid Micro Biosystems.**

AI Summary

Endeavour Medtech Growth II LP, a Guernsey-based investment fund, filed an amended SC 13G/A on January 22, 2024, indicating a change in their ownership of Rapid Micro Biosystems, Inc. (NASDAQ: RMBS) as of December 31, 2023. This filing, an Amendment No. 2, updates their previous disclosures regarding their holdings of RMBS Common Stock, par value $0.01. This matters to investors because it signals that a significant institutional investor has adjusted its position, which could reflect their updated outlook on the company's future performance or strategic direction.

Why It Matters

Changes in significant institutional ownership can influence stock price and reflect a major investor's confidence (or lack thereof) in the company's future prospects.

Risk Assessment

Risk Level: low — This filing is a routine update on institutional ownership and does not inherently signal high risk, though the underlying change in ownership could be positive or negative.

Analyst Insight

Investors should monitor subsequent filings (like a Schedule 13D or future 13G/A) for Endeavour Medtech Growth II LP to understand the magnitude and direction of their ownership change in Rapid Micro Biosystems, Inc. and consider if this aligns with their own investment thesis.

Key Players & Entities

• Endeavour Medtech Growth II LP (company) — the reporting person and institutional investor
• Rapid Micro Biosystems, Inc. (company) — the subject company whose stock is being reported
• Guernsey (company) — place of organization for Endeavour Medtech Growth II LP
• $0.01 (dollar_amount) — par value of Rapid Micro Biosystems' Common Stock
• December 31, 2023 (date) — date of the event requiring the filing
• January 22, 2024 (date) — date the SC 13G/A was filed

FAQ

Key Financial Figures

• $0.01 — me of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 7534

Filing Documents

• d737829dsc13ga.htm (SC 13G/A) — 68KB
• 0001193125-24-012286.txt ( ) — 69KB

(a)

Item 1(a). Name of Issuer Rapid Micro Biosystems, Inc. (the Issuer)

(b)

Item 1(b). Address of the Issuers Principal Executive Offices 100 Pawtucket Boulevard West, Suite 280, Lowell, Massachusetts 01854

(a)

Item 2(a). Names of Persons Filing This Statement is filed on behalf of each of the following persons (collectively, the Reporting Persons): (i) Endeavour Medtech Growth II LP (ii) Endeavour Medtech Growth II Parallel LP (iii) Endeavour Medtech II GP Limited

(b)

Item 2(b). Address of the Principal Business Office, or if none, Residence: The address of the principal business and principal office of each of the Reporting Persons is P.O. Box 656, East Wing Trafalgar Court, Les Banques, St Peter Port, Guernsey GY1 3PP.

(c)

Item 2(c). Citizenship (i) Endeavour Medtech Growth II LP is a Guernsey limited partnership. (ii) Endeavour Medtech Growth II Parallel LP is a Guernsey limited partnership. (i) Endeavour Medtech II GP Limited is a Guernsey limited partnership.

(d)

Item 2(d). Title of Class of Securities Class A Common stock, par value $0.01 per share

(e)

Item 2(e). CUSIP Number 75340L104 Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a: Not applicable. Item 4. (a) Amount Beneficially Owned: Endeavour Medtech Growth II LP 2,217,190 shares of Class A common stock are held of record by Endeavour Medtech Growth II LP (EMG II). Endeavour Medtech II GP Limited (Endeavour GP) is the general partner of EMG II. Endeavour Medtech Growth II Parallel LP 39,909 shares of Class A common stock are held of record by Endeavour Medtech Growth II Parallel LP (EMG II AFF). Endeavour GP is the general partner of EMG II AFF. Item 5. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following . Item 6. Not applicable. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person Not applicable. Item 8. Identification and Classification of Members of the Group Due to the relationships between them, the reporting persons hereunder may be deemed to constitute a group with one another for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934. Item 9. Notice of Dissolution of Group Not applicable. Item 10. Certification By signing below each of the undersigned certifies that, to the best of its or his knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in

View Full Filing

View this SC 13G/A filing on SEC EDGAR